The College has published new guidance on workload prioritisation, reflecting the increasing prevalence of COVID-19 around the country, to support GPs and their teams in making local decisions based on local circumstances
In response to the COVID-19 pandemic, the RCGP and the BMA’s GP committee has prepared joint guidance to help practices across the UK to prioritise the clinical and non-clinical workload in general practice.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment